Neurocrine Biosciences | NBIX - Ordinary Share Capital


Neurocrine Biosciences reported $100.55M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 541M 1000K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Exelixis USD 248.88M 4.82M Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Prothena USD 53.08M 756K Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Repligen USD 56.43M 28K Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Teva Pharmaceutical Industries USD 1.16B 1000K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026